COVID-19 outcomes have genuinely improved since the catastrophic early waves, but the virus itself deserves less credit for that than most people assume. The drop in deaths and hospitalizations is largely the product of widespread immunity built through vaccination and prior infection, better treatments, and clinical experience accumulated over five years. Meanwhile, a collapse in testing and surveillance has made the disease far less visible in daily life, reinforcing the feeling that the problem has mostly resolved itself.
The Immunity Wall That Changed Everything
The single biggest reason COVID feels different now is that almost nobody encounters the virus with a completely naive immune system anymore. By 2024, most adults in high-income countries had been vaccinated, infected, or both. That combination of vaccination plus prior infection, known as hybrid immunity, turns out to be remarkably durable against the worst outcomes. A large systematic review and meta-regression found that hybrid immunity with a primary vaccine series was about 96% effective at preventing hospitalization or severe disease at three months, and that protection barely budged over a full year, remaining around 97%.1The Lancet Infectious Diseases. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression That kind of stability against severe outcomes is striking, and it goes a long way toward explaining why hospitals are no longer overwhelmed the way they were in 2020 and 2021.
The biological reason for this durability is that hybrid immunity generates far more high-quality memory B cells than either infection or vaccination alone. One evidence synthesis estimated those levels at roughly five to ten times higher, with protection against symptomatic disease lasting six to eight months before starting to wane.2PubMed Central. Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination-Evidence Synthesis and Implications for New COVID-19 Vaccines A more recent retrospective cohort study put the gap in even starker terms: people without documented prior infection were over 14 times more likely to develop severe COVID compared with those who had hybrid immunity.3PubMed. Hybrid and vaccination immunity against severe COVID-19 in the post-pandemic era-a retrospective cohort study Protection against catching the virus fades relatively quickly, but protection against ending up in the hospital holds up far better. That distinction matters for how you interpret the current situation: infections keep happening, but fewer of them land people in intensive care.
The Virus Hasn’t Necessarily Gone Soft
A common assumption is that SARS-CoV-2 has evolved to become inherently milder, the way some textbooks describe viruses mellowing over time to keep their hosts alive longer. The reality is more complicated. A study from Hong Kong compared unvaccinated patients hospitalized with the original Wuhan strain against unvaccinated patients hospitalized with Omicron BA.2 and found that the age-specific fatality risk was comparable between the two groups. In other words, Omicron’s intrinsic severity in people with no prior immunity was roughly on par with the ancestral strain; what made Omicron appear so much milder was that most people who caught it had some immune protection.4PubMed. Intrinsic and Effective Severity of Coronavirus Disease 2019 Cases Infected With the Ancestral Strain and Omicron BA.2 Variant in Hong Kong The effective severity dropped dramatically, but the intrinsic severity didn’t.
Animal data does suggest some degree of attenuation. In golden Syrian hamsters, the original Wuhan-like strain caused severe pneumonia and substantial weight loss, while Delta and Omicron produced less dramatic illness, though viral loads in lungs and nasal passages still ran high.5Journal of microbiology, epidemiology and immunobiology. Virulence and tissue tropism of different epidemiologically significant SARS-CoV-2 variants for golden Syrian hamsters The broader evolutionary picture is not as neat as “viruses always become milder.” The trade-off hypothesis, which proposes that viruses face pressure to balance transmissibility and virulence, has been invoked for decades but has also been challenged repeatedly. Trade-offs exist, but they may not follow the simple trajectory people expect, and other life-history traits complicate the picture.6PubMed. Virulence evolution and the trade-off hypothesis: history, current state of affairs and the future There is no evolutionary law guaranteeing that the next dominant variant will be gentler than the last.
What Omicron did gain was an extraordinary ability to reinfect people. One Turkish study tracked reinfection across variants and found it occurred in about 13% of Omicron cases, compared with roughly 1.2% for Delta and under half a percent for Alpha. That makes Omicron reinfections about 30 times more frequent than Alpha reinfections.7PubMed Central. SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants A virus that reinfects easily can sustain itself without needing to be as lethal per case. But “less lethal per case” and “less dangerous overall” are not the same thing when a virus is infecting people multiple times a year.
We Stopped Counting
One of the biggest reasons COVID seems to have faded is that we largely stopped looking for it. Most countries wound down free testing programs, and the shift to home rapid antigen tests means positive results rarely get reported to public health authorities. Research confirmed what many suspected: official COVID-19 case counts increasingly underestimate the number of people who test positive, and they vastly underestimate the total number of true infections.8JAMA Network Open. Unreported SARS-CoV-2 Home Testing and Test Positivity
The tests themselves have become less reliable as the virus has changed. Research has found that several commonly used rapid antigen tests now have diagnostic sensitivities below 30%, with sensitivity near zero in the first 48 hours of infection.9PubMed Central. Rapid antigen testing for COVID-19: Decreasing diagnostic reliability, potential detrimental effects and a lack of evidence to support continued public funding of community-based testing That is a staggering decline from the performance these tests delivered earlier in the pandemic. If you test negative on a rapid test and go about your day, you could easily be infected and contagious. The false sense of security this creates may actually increase transmission rather than reduce it.
Wastewater surveillance has stepped in to fill some of the gap. By sampling sewage for SARS-CoV-2 genetic material, public health agencies can track viral circulation regardless of whether anyone visits a clinic or reports a test. Wastewater data generally correlates well with other indicators and can detect shifts in the epidemic growth rate about two days before hospital admissions reflect the same change.10PubMed Central. The impact of signal variability on COVID-19 epidemic growth rate estimation from wastewater surveillance data Researchers using machine learning on community-level wastewater data have found significant underreporting of COVID cases in the period following the end of testing mandates.11PubMed Central. Community-level wastewater surveillance with machine learning methods to assess underreporting of COVID-19 case counts Wastewater monitoring is now one of the most honest windows into how much virus is actually circulating, and what it shows is that waves keep coming, even when case counts suggest otherwise.
Still More Dangerous Than the Flu
One of the most persistent misconceptions is that COVID has mellowed into something equivalent to seasonal influenza. It hasn’t. A study published in JAMA compared patients hospitalized for COVID against those hospitalized for seasonal influenza during the fall and winter of 2023-2024 and found that COVID patients still had a higher risk of dying, with an adjusted 30-day death rate of about 5.7% compared with about 4.2% for influenza.12JAMA. Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024 A separate study looking at broader populations confirmed the pattern, finding COVID was associated with nearly twice the 30-day mortality risk compared with influenza, with particularly elevated danger for adults under 65, hospitalized patients, and those with a history of heart attack.13PubMed. Increased 30-day mortality risk in COVID-19 compared with seasonal influenza
The gap between COVID and flu has narrowed considerably since 2020, and for most healthy vaccinated adults, a single bout of COVID now feels flu-like in severity. But “feels flu-like” and “carries flu-like risk” are different claims. The tail risk of COVID, the chance that an apparently routine infection leads to hospitalization or death, remains higher than for influenza in most populations studied so far. This distinction is easy to miss when you or everyone you know has had a mild case.
Pandemic Fatigue Changed Behavior, Not Risk
The psychological dimension of “COVID feeling better” is real and well documented. A worldwide assessment of adherence to protective behaviors found that physical distancing dropped steadily over the first several months of the pandemic, with avoidance of gatherings falling by roughly half a point on a five-point scale within the first 150 to 180 days after measures were introduced. Mobility data told the same story: time spent at home dropped while visits to retail and recreation venues rebounded sharply.14Nature Human Behaviour. A worldwide assessment of changes in adherence to COVID-19 protective behaviours and hypothesized pandemic fatigue People adapted their behavior based partly on how tired they were of the restrictions, not only on how dangerous the virus remained.
Research into the cognitive mechanisms behind this found that both risk adaptation (adjusting behavior in response to perceived changes in risk) and habituation (gradually tuning out a persistent threat) accounted for declining protective behaviors. Habituation is the key insight: even if you know the risk hasn’t disappeared, your brain eventually stops treating it as urgent.15PubMed. Health protective behaviours during the COVID-19 pandemic: Risk adaptation or habituation? This helps explain why so many people feel that COVID is essentially over despite ongoing waves. The threat hasn’t changed as much as our emotional response to it.
Treatments That Shifted the Odds
Antiviral treatments are another genuine reason outcomes have improved. Nirmatrelvir-ritonavir, marketed as Paxlovid, has shown substantial effectiveness in preventing severe disease when given early. A matched cohort study from a large U.S. healthcare system estimated an overall effectiveness of about 54% in preventing hospitalization or death within 30 days, which climbed to roughly 80% when the drug was dispensed within five days of symptom onset.16The Lancet Infectious Diseases. Effectiveness of oral nirmatrelvir–ritonavir against severe COVID-19 among patients in a large US health-care system: a matched cohort study A review of retrospective cohort studies confirmed that the drug reduces hospitalization, severe disease progression, and death in high-risk patients, including those with prior immunity from infection or vaccination.17Journal of Renal Injury Prevention. Nirmatrelvir-ritonavir efficacy and safety in high-risk COVID-19 patients: a review of recent retrospective cohort studies – nephrology point of view
The catch is that Paxlovid works best when given fast, ideally within the first few days of symptoms. With testing infrastructure diminished and many people not bothering to confirm they have COVID, the window for effective treatment often closes before anyone reaches for a prescription. An antiviral that works well on paper only matters if people can access it in time, and the current environment makes that harder than it should be.
Who Still Faces Serious Danger
Population-level averages mask enormous variation in individual risk. A systematic review and meta-analysis of immunocompromised people during the Omicron era found that transplant recipients had nearly seven times the risk of death and hospitalization compared with the general population.18PubMed. Risk of Severe Outcomes From COVID-19 in Immunocompromised People During the Omicron Era: A Systematic Review and Meta-Analysis For people with weakened immune systems, whether from organ transplants, cancer treatment, autoimmune medications, or other conditions, COVID in 2025 is not the mild inconvenience it has become for most healthy adults. Their immune systems cannot mount the robust hybrid response that protects everyone else, which means each new infection carries substantial risk.
Older adults also remain disproportionately affected. Research in people aged 65 and older found that COVID infection was associated with a greater risk of subsequent dementia diagnosis, and this elevated risk appeared to be consistent across both immunocompromised and non-immunocompromised individuals in that age group.19Innovation in Aging. Risk of Dementia in Immunocompromised and Non-immunocompromised Persons with COVID-19 Infection The connection between COVID and neurological consequences remains an active area of research, but the signal is strong enough to take seriously, particularly for people who are already at higher baseline risk for cognitive decline.
Long COVID in the Omicron Era
One area where Omicron does appear to have brought genuine improvement is in the risk of long-lasting symptoms. A study comparing long-term outcomes across variants found that Omicron was associated with roughly 70% lower odds of developing long COVID or post-COVID syndrome compared with the Alpha variant, after adjusting for other factors like ICU admission and antiviral treatment.20PubMed Central. COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants That’s a meaningful reduction, and it aligns with clinical experience suggesting that the chronic fatigue, brain fog, and other symptoms that plagued many early-pandemic patients are less common after Omicron infections.
But “less common” does not mean rare, especially when so many people are getting infected and reinfected. Even a smaller percentage of a very large number produces a lot of affected individuals. And whether the lower long COVID rate holds steady as the virus continues to evolve is an open question. For now, if you are weighing the risks of a current infection, the long COVID picture is genuinely better than it was in 2020 or 2021, but it has not disappeared.
Children and MIS-C
For parents, one of the more reassuring trends is the decline of Multisystem Inflammatory Syndrome in Children, the serious inflammatory condition that sometimes followed COVID infection in kids. A single-center cohort study found a clear decrease in MIS-C incidence relative to infections over time, but with an important caveat: the severity of MIS-C cases that did occur remained essentially unchanged across variants, including Omicron.21PubMed Central. Dynamics of Multisystem Inflammatory Syndrome in Children (MIS-C) associated to COVID-19: steady severity despite declining cases and new SARS-CoV-2 variants—a single-center cohort study In other words, later variants appear less likely to trigger MIS-C, but when they do, the condition is just as dangerous as it ever was.
A broader epidemiological study found that the odds of shock in MIS-C patients decreased over time, and pediatric COVID cases during the Omicron wave tended to involve shorter hospital stays and less ICU use compared with Delta.22PubMed Central. Epidemiology and Severity of Illness of MIS-C and Kawasaki Disease During the COVID-19 Pandemic23PubMed Central. Decreased Clinical Severity of Pediatric Acute COVID-19 and MIS-C and Increase of Incidental Cases during the Omicron Wave in Comparison to the Delta Wave Some of the apparent mildness during Omicron may reflect increased incidental diagnoses, where children were hospitalized for something else and happened to test positive. But the overall trajectory for children has improved meaningfully, driven by some combination of variant characteristics, population immunity, and accumulated clinical knowledge.
Excess Mortality Tells a Different Story
If COVID is truly getting better, you would expect excess mortality, the number of deaths above what would normally be predicted, to have fallen back to baseline by now. In many places, it hasn’t. A multi-country ecological study found substantial excess cumulative mortality persisting through 2022 across all 21 participating countries. Several of those countries actually experienced higher excess mortality in 2022 than in 2021, including places like Australia, Denmark, Israel, and Norway that had managed relatively well in earlier phases of the pandemic.24International Journal of Epidemiology. Sustained excess all-cause mortality post COVID-19 in 21 countries: an ecological investigation
Interpreting excess mortality is genuinely difficult. In Germany, the peak of excess deaths in 2022 coincided with a severe influenza wave, and the weekly death rate during that period was higher than during any individual SARS-CoV-2 wave by either of the two methods researchers used to calculate it.25PubMed Central. All‑cause excess mortality in Germany peaked during the late‑2022 influenza period, exceeding peaks during SARS‑CoV‑2 waves (2020-2023) That does not mean COVID is irrelevant to the excess mortality picture, but it does mean that the post-pandemic health landscape involves multiple overlapping threats, including the possibility that COVID weakened people’s immune defenses in ways that made other infections more lethal. Disentangling these factors will keep researchers busy for years.
A Virus That Surges in Summer and Winter
One reason COVID keeps catching people off guard is that it doesn’t follow the tidy winter-only pattern most people associate with respiratory viruses. Analysis of global surveillance data has identified a semiannual cycle with alternating peaks in winter and summer, a pattern observed consistently across different regions, though the size and timing of peaks vary by location.26PubMed Central. Semiannual seasonality of COVID-19 with alternating peaks in winter and summer In tropical regions like India, COVID has shown consistent summer surges driven by people retreating indoors to escape the heat, recreating the same crowded indoor conditions that fuel winter waves in temperate climates.27PubMed Central. Rethinking COVID-19 seasonality: A summer respiratory virus in the tropics, contrast to influenza
This dual-peak seasonality means that people who assume they only need to worry about COVID during flu season are likely to be caught off guard by summer waves. It also complicates vaccine timing: a booster timed perfectly for a winter wave may have waning protection by the time a summer surge arrives. The virus’s combination of thermal resilience, efficient transmission before symptoms appear, and its ability to infect tissue beyond just the respiratory tract all help it persist outside the classic winter window that constrains influenza.
For most people, the honest answer to the title question is “both.” COVID outcomes are genuinely and meaningfully better than they were in 2020, primarily because your immune system has encountered the virus or a vaccine against it, and treatments work when given quickly. But a significant portion of the improvement is perceptual: you test less, you hear about it less, and your brain has habituated to a threat that is still killing more people than seasonal influenza and still poses serious risks to vulnerable groups. The virus circulates year-round in waves that surveillance barely captures, and the next variant is under no evolutionary obligation to be milder than the last.